Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $500.0M zero-coupon convertible notes due 2031, with initial purchasers’ $50.0M additional-purchase option.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $500.0M zero-coupon convertible notes due 2031, with initial purchasers’ $50.0M additional-purchase option
- Approximately $328.8M proceeds allocated to repurchase $222.0M principal of 1.5% convertible notes due 2026
- Remaining proceeds for general corporate purposes, additional 2026 Notes repurchases, or maturity repayment
- Refinancing extends debt maturity but introduces potential future equity dilution upon conversion
Item EX-99.1 · Exhibit EX-99.1
- $500M 0% convertible notes due June 15, 2031, extending maturity without regular cash interest
- $328.8M proceeds earmarked to repurchase $222.0M principal of 1.5% notes due 2026, reducing near-term refinancing exposure
- Initial conversion price $107.48, a 40% premium to PTCT’s $76.77 closing price, limiting immediate dilution risk
- Remaining proceeds available for general corporate purposes, additional 2026 note repurchases, or maturity repayment
- Potential dilution and future share-price sensitivity from conversion at 9.3042 shares per $1,000 note principal
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.